Abstract
Oral HIV pre-exposure prophylaxis (PrEP) effectively prevents infection when taken during periods of risk, however, its population-level effectiveness is hindered by incomplete uptake, adherence, and retention. Since PrEP became available free-of-cost in British Columbia (BC), Canada, in January 2018, uptake has been rapid among gay, bisexual, and other men who have sex with men (GBM). Epidemiological evidence suggests adding PrEP onto a background of generalized access to free antiretroviral therapy, under the BC Treatment as Prevention (TasP) strategy, had a synergistic effect on reducing new infections. Here, we sought to evaluate the impact of PrEP on HIV transmission and drug resistance in phylogenetic clusters. In a retrospective cohort study, we evaluated whether baseline HIV drug resistance and phylogenetic clustering were more likely among newly diagnosed PrEP users in BC (n=39) compared to non-PrEP users (n=566) during the same diagnosis period from October 23, 2018 to December 5, 2022. Subsequently, we evaluated heterogeneity in PrEP-related reductions of the effective reproduction number (Re) across BC, key populations, and phylogenetic clusters. Stochastic branching processes of phylogenetic clusters informed by Re preceding PrEP were used to estimate diagnoses averted via PrEP. Newly HIV diagnosed PrEP users were significantly more likely than non-PrEP users to join phylogenetic clusters and carry baseline nucleoside-analogue reverse transcriptase inhibitor (NRTI) resistance-associated mutation M184I/V. Despite reductions in growth rate and Re in the GBM population overall and in 50% of active GBM-predominant clusters following PrEP availability, we highlight predominantly GBM and PWID clusters with high or increasing Re. Across active phylogenetic clusters and non-clustered new diagnoses, we estimate PrEP averted approximately 20 new HIV diagnoses per year in BC since 2018. These findings highlight how PrEP has reduced HIV burden, while illuminating groups that could benefit from prioritized PrEP education, access, and retention.
Competing Interest Statement
JSGM received institutional grants from Gilead Sciences, Merck, and ViiV Healthcare. CJB has received grants and honoraria paid to his institution from Merck, Gilead Sciences and ViiV Healthcare. All other authors declare no competing interests.
Funding Statement
The study was funded by the British Columbia Centre for Excellence in HIV/AIDS, Providence Health Care, Canadian Institutes of Health Research, Public Health Agency of Canada, Genome Canada, and Genome BC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of University of British Columbia - Providence Health Care Research Institute gave ethical approval for this work (REB #H20-02859) on December 7, 2020 and amended September 8, 2022.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data sharing
The BC-CfE is prohibited from making individuals’ data publicly available due to provisions in our service contracts, institutional policy, and ethical requirements. Code available upon request.
